Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

MannKind Corporation

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WESTLAKE VILLAGE, CALIF., SEPT. 29, 2025 (GLOBE NEWSWIRE) -- MANNKIND CORPORATION (NASDAQ: MNKD), A COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE INHALED THERAPEUTIC PRODUCTS AND DEVICES FOR PATIENTS WITH ENDOCRINE AND ORPHAN LUNG DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF AJAY AHUJA, MD, MBA, AS CHIEF MEDICAL OFFICER, EFFECTIVE TODAY.

MANNKIND APPOINTS DR. AJAY AHUJA AS EXECUTIVE VICE PRESIDENT AND CHIEF MEDICAL OFFICER

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF SCPHARMACEUTICALS INC. (NASDAQGS: SCPH) TO MANNKIND CORPORATION (NASDAQGM: MNKD). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF SCPHARMACEUTICALS WOULD RECEIVE A CASH PAYMENT OF $5.35 PER SHARE PLUS ONE NON-TRADABLE CONTINGENT VALUE RIGHT (CVR) PER SHARE PAYABLE UPON ACHIEVING SP.

SCPHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF SCPHARMACEUTICALS INC. - SCPH

DANBURY, CONN.ANDWESTLAKE VILLAGE, CALIF., AUG. 27, 2025 (GLOBE NEWSWIRE) -- MANNKIND CORPORATION(NASDAQ: MNKD), A COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE INHALED THERAPEUTIC PRODUCTS AND DEVICES FOR PATIENTS WITH ENDOCRINE AND ORPHAN LUNG DISEASES, ANNOUNCED ITS PARTICIPATION AT THE UPCOMING INVESTOR CONFERENCES. MANNKIND'S CHIEF EXECUTIVE OFFICER MICHAEL CASTAGNA, PHARMD, AND CHIEF FINANCIAL OFFICERCHRIS PRENTISSWILL SHARE UPDATES DURING THE FOLLOWING INVESTOR CONFERENCES:

MANNKIND TO PRESENT AT UPCOMING INVESTOR CONFERENCES

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND THE LAW FIRM OF KAHN SWICK & FOTI, LLC (KSF) ARE INVESTIGATING THE PROPOSED SALE OF SCPHARMACEUTICALS INC. (NASDAQGS: SCPH) TO MANNKIND CORPORATION (NASDAQGM: MNKD). UNDER THE TERMS OF THE PROPOSED TRANSACTION, SHAREHOLDERS OF SCPHARMACEUTICALS WOULD RECEIVE A CASH PAYMENT OF $5.35 PER SHARE PLUS ONE NON-TRADABLE CONTINGENT VALUE RIGHT (CVR) PER SHARE PAYABLE UPON ACHIEVING SPECIFI.

DANBURY, CONN. AND BURLINGTON, MASS., AUG. 25, 2025 (GLOBE NEWSWIRE) -- MANNKIND CORPORATION (NASDAQ: MNKD) AND SCPHARMACEUTICALS INC. (NASDAQ: SCPH) TODAY ANNOUNCED THE SIGNING OF A DEFINITIVE MERGER AGREEMENT FOR MANNKIND TO ACQUIRE SCPHARMACEUTICALS.

MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIOMETABOLIC AND LUNG DISEASES

ACQUISITION EXPECTED TO DIVERSIFY AND ACCELERATE DOUBLE-DIGIT REVENUE GROWTH WITH FUROSCIX  , AN INNOVATIVE TREATMENT FOR EDEMA DUE TO CHRONIC HEART FAILURE AND CHRONIC KIDNEY DISEASE, ADDRESSING SIGNIFICANT UNMET NEED UPFRONT CASH PAYMENT OF $5.35 PER SHARE PLUS ONE NON-TRADABLE CONTINGENT VALUE RIGHT (CVR) PER SHARE PAYABLE UPON ACHIEVING SPECIFIC REGULATORY AND NET SALES MILESTONES WORTH UP TO $1.00 PER CVR IN CASH UPFRONT CASH PAYMENT REPRESENTS A 36% PREMIUM TO SCPHARMACEUTICALS' 90 TRADING DAY VWAP, AND TOTAL CONSIDERATION OF UP TO $6.35 PER SHARE REPRESENTS UP TO A 31% PREMIUM TO SCPHARMACEUTICALS' CLOSING PRICE ON AUGUST 22, 2025 STRENGTHENS ORGANIZATION BY INTEGRATING SCPHARMACEUTICALS' ESTABLISHED COMMERCIAL AND MEDICAL CAPABILITIES INTO MANNKIND'S EXISTING INFRASTRUCTURE FUROSCIX READYFLOW AUTOINJECTOR ON TRACK FOR Q3 2025 SNDA SUBMISSION, POTENTIALLY UNLOCKING ADDITIONAL MARKET OPPORTUNITY MANNKIND TO HOST CONFERENCE CALL TODAY AT 8:30 A.M. (ET) DANBURY, CONN.

STRENGTHENS MANNKIND'S CAPITAL STRUCTURE WITH FLEXIBLE, LONG-TERM, NON-DILUTIVE FUNDING MANNKIND TO RECEIVE $75 MILLION IN CASH AT CLOSING DANBURY, CONN. AND WESTLAKE VILLAGE, CALIF.

MANNKIND AND BLACKSTONE ANNOUNCE UP TO $500 MILLION STRATEGIC FINANCING AGREEMENT

2Q 2025 REVENUES OF $76.5M, +6% V. 2Q 2024 YTD 2025 REVENUES OF $154.9M, +12% V.

MANNKIND CORPORATION REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

DANBURY, CONN. AND WESTLAKE VILLAGE, CALIF.

MANNKIND CORPORATION TO HOLD 2025 SECOND QUARTER FINANCIAL RESULTS CONFERENCE CALL ON AUGUST 6, 2025

MANNKIND TO HIGHLIGHT DATA FROM RECENT PEDIATRIC AND ADULT STUDIES OF INHALED INSULIN (AFREZZA) AT AMERICAN DIABETES ASSOCIATION'S 85TH SCIENTIFIC SESSION

MANNKIND TO HIGHLIGHT DATA FROM RECENT PEDIATRIC AND ADULT STUDIESOF INHALED INSULIN (AFREZZA) AT AMERICAN DIABETES ASSOCIATION'S85TH SCIENTIFIC SESSIONS IN CHICAGO, JUNE 20-23

WESTLAKE VILLAGE, CALIF., MAY 27, 2025 (GLOBE NEWSWIRE) -- MANNKIND CORPORATION (NASDAQ: MNKD) WILL TEAM UP WITH NTT INDYCAR SERIES DRIVER CONOR DALY, WHO IS LIVING WITH TYPE 1 DIABETES (T1D) FOR A ONE-OF-A-KIND EXPERIENCE WITH DETROIT AREA YOUTH AND FAMILIES DURING THE WEEK OF THE CHEVROLET DETROIT GRAND PRIX IN DOWNTOWN DETROIT.

INDYCAR DRIVER CONOR DALY TO SHARE HIS PERSONAL DIABETES STORY AND RACE GO-KARTS WITH DETROIT AREA YOUTH ON THURSDAY, MAY 29

DANBURY, CONN. AND WESTLAKE VILLAGE, CALIF., MAY 13, 2025 (GLOBE NEWSWIRE) -- MANNKIND CORPORATION(NASDAQ: MNKD), A COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE INHALED THERAPEUTIC PRODUCTS AND DEVICES FOR PATIENTS WITH ENDOCRINE AND ORPHAN LUNG DISEASES, ANNOUNCED ITS PARTICIPATION AT THE UPCOMING INVESTOR CONFERENCES. MANNKIND'S CHIEF EXECUTIVE OFFICER MICHAEL CASTAGNA, PHARMD, AND CHIEF FINANCIAL OFFICERCHRIS PRENTISSWILL SHARE UPDATES DURING THE FOLLOWING INVESTOR CONFERENCES, BOTH BEING HELD IN NEW YORK CITY:

MannKind Corporation

MNKD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MannKind Corporation

MNKD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MNKD